Cascadian Therapeutics, Inc. (NASDAQ:CASC) Rating Reiterated by Cantor Fitzgerald

Cascadian Therapeutics, Inc. (NASDAQ:CASC)‘s stock had its “hold” rating reiterated by Cantor Fitzgerald in a report issued on Monday, September 11th. They currently have a $4.00 target price on the biopharmaceutical company’s stock. Cantor Fitzgerald’s target price points to a potential downside of 2.20% from the stock’s previous close.

The analysts wrote, “Pooled analysis from Phase Ib trial in HER2+ metastatic breast cancer patients with or without brain metastases demonstrated similarity in PFS between two groups (264P), which is a secondary endpoint in the HER2CLIMB trial.””

CASC has been the topic of several other reports. Zacks Investment Research downgraded shares of Cascadian Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, May 19th. ValuEngine downgraded shares of Cascadian Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Friday, June 2nd. Cowen and Company reiterated a “buy” rating on shares of Cascadian Therapeutics in a report on Wednesday, August 9th. Finally, Barclays PLC began coverage on shares of Cascadian Therapeutics in a report on Wednesday, September 6th. They issued an “underweight” rating and a $4.00 price target on the stock. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and three have issued a buy rating to the stock. Cascadian Therapeutics currently has a consensus rating of “Hold” and an average price target of $5.63.

Shares of Cascadian Therapeutics (NASDAQ:CASC) traded down 0.24% during trading on Monday, hitting $4.09. The stock had a trading volume of 351,338 shares. The company’s market capitalization is $206.76 million. Cascadian Therapeutics has a 52 week low of $3.18 and a 52 week high of $10.98. The company’s 50 day moving average price is $3.71 and its 200 day moving average price is $3.92.

Cascadian Therapeutics (NASDAQ:CASC) last issued its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.30) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.36) by $0.06. During the same quarter in the previous year, the firm posted ($1.57) EPS. Analysts predict that Cascadian Therapeutics will post $5.02 earnings per share for the current year.

WARNING: This article was originally reported by BBNS and is the property of of BBNS. If you are viewing this article on another site, it was copied illegally and republished in violation of United States & international copyright and trademark laws. The legal version of this article can be read at https://baseballnewssource.com/markets/cantor-fitzgerald-reiterates-hold-rating-for-cascadian-therapeutics-inc-casc/1633568.html.

A number of institutional investors have recently added to or reduced their stakes in CASC. NEA Management Company LLC boosted its position in Cascadian Therapeutics by 405.9% in the 1st quarter. NEA Management Company LLC now owns 9,064,575 shares of the biopharmaceutical company’s stock valued at $37,527,000 after buying an additional 7,272,909 shares during the period. Baupost Group LLC MA boosted its position in Cascadian Therapeutics by 109.3% in the 1st quarter. Baupost Group LLC MA now owns 8,721,079 shares of the biopharmaceutical company’s stock valued at $36,105,000 after buying an additional 4,554,413 shares during the period. Redmile Group LLC purchased a new stake in shares of Cascadian Therapeutics in the 1st quarter worth approximately $16,860,000. Vanguard Group Inc. lifted its position in shares of Cascadian Therapeutics by 116.7% in the 1st quarter. Vanguard Group Inc. now owns 1,423,843 shares of the biopharmaceutical company’s stock worth $5,895,000 after purchasing an additional 766,725 shares during the period. Finally, Sphera Funds Management LTD. purchased a new stake in shares of Cascadian Therapeutics in the 1st quarter worth approximately $2,406,000. 82.55% of the stock is owned by institutional investors.

About Cascadian Therapeutics

Cascadian Therapeutics, Inc, formerly Oncothyreon Inc, is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutic products for the treatment of cancer. The Company’s clinical-stage product candidate includes ONT-380, an orally active and selective small-molecule human epidermal growth factor receptor (HER) 2 inhibitor.

Analyst Recommendations for Cascadian Therapeutics (NASDAQ:CASC)

Receive News & Ratings for Cascadian Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cascadian Therapeutics Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Houston Astros Relying on Justin Verlander to Save Their Season
Houston Astros Relying on Justin Verlander to Save Their Season
Clayton Kershaw Gets Chance to Pitch LA into Fall Classic
Clayton Kershaw Gets Chance to Pitch LA into Fall Classic
Aaron Judge and Gary Sanchez Have Break Out Games
Aaron Judge and Gary Sanchez Have Break Out Games
Justin Turner Joining Postseason Legends
Justin Turner Joining Postseason Legends
PED Use Cost Alex Rodriguez Millions and His Reputation
PED Use Cost Alex Rodriguez Millions and His Reputation
Yankees to Send Masahiro Tanaka Against Astros in Game 1
Yankees to Send Masahiro Tanaka Against Astros in Game 1


Leave a Reply

 
© 2006-2017 BBNS.